KR102941538B1 - 골관절염을 치료하기 위한 c-형 나트륨이뇨 펩타이드 변이체의 용도 - Google Patents

골관절염을 치료하기 위한 c-형 나트륨이뇨 펩타이드 변이체의 용도

Info

Publication number
KR102941538B1
KR102941538B1 KR1020187019166A KR20187019166A KR102941538B1 KR 102941538 B1 KR102941538 B1 KR 102941538B1 KR 1020187019166 A KR1020187019166 A KR 1020187019166A KR 20187019166 A KR20187019166 A KR 20187019166A KR 102941538 B1 KR102941538 B1 KR 102941538B1
Authority
KR
South Korea
Prior art keywords
cnp
gly
cartilage
variant
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187019166A
Other languages
English (en)
Korean (ko)
Other versions
KR20180088459A (ko
Inventor
찰스 에이. 오닐
토드 엠. 오페니어
제이슨 케이. 핑크스태프
Original Assignee
바이오마린 파머수티컬 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오마린 파머수티컬 인크. filed Critical 바이오마린 파머수티컬 인크.
Publication of KR20180088459A publication Critical patent/KR20180088459A/ko
Application granted granted Critical
Publication of KR102941538B1 publication Critical patent/KR102941538B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187019166A 2015-12-08 2016-12-08 골관절염을 치료하기 위한 c-형 나트륨이뇨 펩타이드 변이체의 용도 Active KR102941538B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08
US62/264,682 2015-12-08
PCT/US2016/065520 WO2017100400A2 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis

Publications (2)

Publication Number Publication Date
KR20180088459A KR20180088459A (ko) 2018-08-03
KR102941538B1 true KR102941538B1 (ko) 2026-03-19

Family

ID=59013378

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187019166A Active KR102941538B1 (ko) 2015-12-08 2016-12-08 골관절염을 치료하기 위한 c-형 나트륨이뇨 펩타이드 변이체의 용도

Country Status (17)

Country Link
US (2) US11202819B2 (https=)
EP (2) EP4019038A3 (https=)
JP (1) JP7104625B2 (https=)
KR (1) KR102941538B1 (https=)
CN (1) CN108697766A (https=)
AU (2) AU2016365751B2 (https=)
CA (1) CA3007315A1 (https=)
DK (1) DK3386531T3 (https=)
ES (1) ES2901769T3 (https=)
HR (1) HRP20211908T1 (https=)
HU (1) HUE057083T2 (https=)
IL (1) IL259690B2 (https=)
MX (1) MX2018006986A (https=)
PL (1) PL3386531T3 (https=)
PT (1) PT3386531T (https=)
RU (1) RU2759679C2 (https=)
WO (1) WO2017100400A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3400019T (lt) 2016-01-08 2022-12-12 Ascendis Pharma Growth Disorders A/S Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
IL297375B2 (en) 2016-01-08 2024-02-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low NPR–C binding
MX2018008061A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
NZ743487A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
AU2019260810A1 (en) * 2018-04-27 2020-11-19 Remy Biosciences, Inc. New medical devices, delivery vehicles and manufacturing thereof
EP3923906A1 (en) * 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
WO2022115563A1 (en) * 2020-11-25 2022-06-02 Prolynx Llc Extended release hydrogel conjugates of c-natriuretic peptides
US20240238428A1 (en) * 2021-05-11 2024-07-18 Texas Tech University System Targeted selenium conjugates as countermeasures for viral and cellular pathogens
AU2022407450A1 (en) * 2021-12-07 2024-07-11 Biomarin Pharmaceutical Inc. CNP Therapy
EP4612167A1 (en) 2022-11-02 2025-09-10 Novo Nordisk A/S Cnp compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
KR20250098109A (ko) * 2023-12-21 2025-07-01 주식회사 펩트론 나트륨이뇨 펩타이드 유사체 및 이의 용도
CN117801123B (zh) * 2024-02-29 2024-05-03 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
CN1960757A (zh) * 2004-03-31 2007-05-09 中尾一和 身高增加用组合物
CN1960758B (zh) * 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
AR069409A1 (es) 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
ES2608457T3 (es) * 2009-05-20 2017-04-11 Biomarin Pharmaceutical Inc. Variantes de péptido natriurético de tipo C
JP6055779B2 (ja) * 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法

Also Published As

Publication number Publication date
JP7104625B2 (ja) 2022-07-21
IL259690A (en) 2018-07-31
HUE057083T2 (hu) 2022-04-28
WO2017100400A2 (en) 2017-06-15
EP3386531B1 (en) 2021-10-13
US12214015B2 (en) 2025-02-04
IL259690B (en) 2022-10-01
CA3007315A1 (en) 2017-06-15
WO2017100400A3 (en) 2017-10-26
RU2759679C2 (ru) 2021-11-16
AU2016365751B2 (en) 2023-12-21
US11202819B2 (en) 2021-12-21
EP3386531A2 (en) 2018-10-17
AU2016365751A1 (en) 2018-06-21
RU2021132347A (ru) 2022-03-24
KR20180088459A (ko) 2018-08-03
RU2018124600A3 (https=) 2020-01-13
MX2018006986A (es) 2018-09-05
JP2019505486A (ja) 2019-02-28
PL3386531T3 (pl) 2022-02-28
HRP20211908T1 (hr) 2022-03-04
DK3386531T3 (da) 2022-01-03
PT3386531T (pt) 2021-12-29
CN108697766A (zh) 2018-10-23
ES2901769T3 (es) 2022-03-23
US20190247467A1 (en) 2019-08-15
EP4019038A2 (en) 2022-06-29
US20220160836A1 (en) 2022-05-26
EP4019038A3 (en) 2022-09-28
AU2024201852A1 (en) 2024-04-11
IL259690B2 (en) 2023-02-01
RU2018124600A (ru) 2020-01-13

Similar Documents

Publication Publication Date Title
KR102941538B1 (ko) 골관절염을 치료하기 위한 c-형 나트륨이뇨 펩타이드 변이체의 용도
JP5718909B2 (ja) Ｃ型ナトリウム利尿ペプチドの変異体
US8377884B2 (en) Variants of C-type natriuretic peptides
RU2850341C2 (ru) Применение вариантов натрийуретического пептида типа c для лечения остеоартрита
HK40074902A (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
HK1262398B (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
HK40124042A (en) Variants of c-type natriuretic peptide
HK40130436A (en) Variants of c-type natriuretic peptide
HK1239519B (en) Variants of c-type natriuretic peptide
HK1168279B (en) Variants of c-type natriuretic peptide

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)